CTT Pharmaceutical CEO acquires additional shares for $775

Published 31/03/2025, 15:44
CTT Pharmaceutical CEO acquires additional shares for $775

In recent filings with the Securities and Exchange Commission, CTT Pharmaceutical (TADAWUL:2070) Holdings, Inc. (OTC:CTTH) reported that its CEO, Ryan Khouri, has acquired an additional 15,510 shares of the company. The purchase, completed on March 31, 2025, was made at a price of $0.05 per share, amounting to a total transaction value of $775. The transaction occurred at the current market price, with the stock trading near its 52-week range of $0.01 to $0.15. According to InvestingPro, the company maintains a market capitalization of $2.82M and shows a high shareholder yield. Following this acquisition, Khouri’s total direct ownership stands at 6,590,416 shares. This transaction reflects the CEO’s ongoing commitment to the company amidst its operations in the gold and silver ores sector. InvestingPro analysis reveals the company trades at a low Price/Book multiple, with an overall Financial Health rating of FAIR. Subscribers can access 8 additional exclusive ProTips and detailed valuation metrics for CTTH.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.